Moreover, there was a strong rationale for mTOR inhibitors (mTORi) effects in many hematological diseases due to the associated hyperactivation of mTOR, as in acute leukemia, lymphoma, multiple myeloma, Waldenström macroglobulinemia, and GVHD [22,32]. The gene discussed is MTOR; the disease is graft versus host disease.